See more : Easy Trip Planners Limited (EASEMYTRIP.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Galectin Therapeutics Inc. (GALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galectin Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bally’s Corporation (BALY) Income Statement Analysis – Financial Results
- Kunshan Huguang Auto Harness Co.,Ltd. (605333.SS) Income Statement Analysis – Financial Results
- ECN Capital Corp. (ECNCF) Income Statement Analysis – Financial Results
- MongoDB, Inc. (MDB) Income Statement Analysis – Financial Results
- Kudelski SA (0QNQ.L) Income Statement Analysis – Financial Results
Galectin Therapeutics Inc. (GALT)
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 33.00K | 32.00K | 41.00K | 36.00K | 35.00K | 0.00 | 1.00K | 7.00K | 7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.33M | 6.46M | 7.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -33.00K | -32.00K | -41.00K | -36.00K | -35.00K | 0.00 | -1.00K | -7.00K | -7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.33M | -6.46M | -7.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.13M | 31.74M | 23.82M | 17.98M | 7.47M | 6.47M | 11.72M | 15.33M | 13.11M | 8.43M | 5.69M | 4.53M | 3.55M | 1.07M | 1.11M | 1.77M | 2.05M | 3.02M | 3.04M | 3.04M | 1.95M | 1.48M | 893.46K | 100.00K |
| General & Administrative | 5.90M | 6.62M | 6.36M | 5.47M | 5.97M | 7.13M | 4.53M | 6.16M | 6.97M | 7.01M | 6.42M | 5.37M | 6.86M | 3.82M | 4.98M | 3.55M | 4.40M | 4.03M | 3.62M | 4.26M | 2.99M | 1.80M | 1.29M | 70.00K |
| Selling & Marketing | 44.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.94M | 6.62M | 6.36M | 5.47M | 5.97M | 7.13M | 4.53M | 6.16M | 6.97M | 7.01M | 6.42M | 5.37M | 6.86M | 3.82M | 4.98M | 3.55M | 4.40M | 4.03M | 3.62M | 4.26M | 2.99M | 1.80M | 1.29M | 70.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.07M | 38.35M | 30.18M | 23.44M | 13.44M | 13.60M | 16.25M | 21.48M | 20.08M | 15.43M | 12.10M | 9.90M | 10.41M | 4.88M | 6.09M | 5.33M | 6.46M | 7.05M | 6.66M | 7.30M | 4.94M | 3.29M | 2.18M | 170.00K |
| Cost & Expenses | 38.07M | 38.35M | 30.18M | 23.44M | 13.44M | 13.60M | 16.25M | 21.48M | 20.08M | 15.43M | 12.10M | 9.90M | 10.41M | 4.88M | 6.09M | 5.33M | 6.46M | 7.05M | 6.66M | 7.30M | 4.94M | 3.29M | 2.18M | 170.00K |
| Interest Income | 0.00 | 52.00K | 3.00K | 66.00K | 231.00K | 38.00K | 24.00K | 45.00K | 52.00K | 42.00K | 16.00K | 24.00K | 18.00K | 6.00K | 3.00K | 30.00K | 102.00K | 281.00K | 111.00K | 124.00K | 68.93K | 24.26K | 24.92K | 0.00 |
| Interest Expense | 2.56M | 1.03M | 489.00K | 87.00K | 87.00K | 336.00K | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 350.00K | 1.85M | 0.00 | 0.00 | 3.88K | 415.42K | 0.00 | 0.00 |
| Depreciation & Amortization | 38.07M | 32.00K | 41.00K | 36.00K | 35.00K | 1.00K | 1.00K | 7.00K | 7.00K | 10.00K | 12.00K | 9.00K | 9.00K | 12.00K | 37.00K | 49.00K | 64.00K | 67.00K | 81.00K | 81.00K | 89.17K | 211.18K | 159.47K | -20.00K |
| EBITDA | -202.00K | -37.71M | -30.00M | -23.34M | -13.17M | -13.56M | -16.23M | -21.47M | -20.07M | -15.78M | -12.08M | -9.67M | -10.91M | -5.62M | -7.43M | -3.10M | -9.02M | -1.28M | -6.77M | -7.10M | -4.85M | -3.08M | -2.02M | -190.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -38.07M | -38.35M | -30.18M | -23.44M | -13.44M | -13.60M | -16.25M | -21.48M | -20.08M | -15.43M | -12.10M | -9.90M | -10.41M | -4.88M | -6.09M | -5.33M | -6.46M | -7.05M | -6.66M | -7.30M | -4.94M | -3.29M | -2.18M | -170.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.99M | -424.00K | -348.00K | -21.00K | 144.00K | -298.00K | 12.00K | 45.00K | 52.00K | -358.00K | 16.00K | 224.00K | -506.00K | -746.00K | -1.37M | 2.18M | -2.98M | 3.86M | 111.00K | 124.00K | 65.05K | -391.16K | 0.00 | -20.00K |
| Income Before Tax | -41.07M | -38.78M | -30.53M | -23.47M | -13.29M | -13.90M | -16.24M | -21.44M | -20.03M | -15.79M | -12.09M | -9.68M | -10.92M | -5.63M | -7.46M | -3.15M | -9.43M | -3.19M | -6.54M | -7.18M | -4.87M | -3.68M | 0.00 | -190.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 424.00K | 448.00K | 51.00K | 87.00K | -123.14K | 24.00K | 0.00 | 0.00 | -52.00K | 16.00K | 200.00K | 506.00K | 746.00K | 1.37M | -2.18M | 2.98M | -3.86M | 0.00 | 0.00 | 0.00 | 0.00 | 1.79M | 0.00 |
| Net Income | -41.07M | -39.20M | -30.98M | -23.52M | -13.38M | -13.90M | -16.24M | -21.44M | -20.03M | -15.79M | -12.09M | -9.68M | -10.92M | -5.63M | -7.46M | -3.15M | -9.43M | -3.19M | -6.54M | -7.18M | -4.87M | -3.68M | -3.97M | -190.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.74 | -0.66 | -0.53 | -0.41 | -0.26 | -0.35 | -0.46 | -0.73 | -0.83 | -0.72 | -0.72 | -0.64 | -0.91 | -0.60 | -0.93 | -0.40 | -1.45 | -0.67 | -1.44 | -1.67 | -1.37 | -1.35 | -1.75 | -0.09 |
| EPS Diluted | -0.74 | -0.66 | -0.53 | -0.41 | -0.26 | -0.35 | -0.46 | -0.73 | -0.83 | -0.72 | -0.72 | -0.64 | -0.91 | -0.60 | -0.93 | -0.40 | -1.45 | -0.67 | -1.44 | -1.67 | -1.37 | -1.35 | -1.75 | -0.09 |
| Weighted Avg Shares Out | 60.16M | 59.39M | 58.53M | 57.03M | 52.24M | 39.41M | 35.52M | 29.22M | 24.12M | 21.85M | 16.87M | 15.13M | 11.99M | 9.38M | 8.05M | 7.80M | 6.50M | 4.75M | 4.55M | 4.29M | 3.56M | 2.73M | 2.27M | 2.06M |
| Weighted Avg Shares Out (Dil) | 60.16M | 59.39M | 58.53M | 57.03M | 52.24M | 39.41M | 35.52M | 29.22M | 24.12M | 21.85M | 16.87M | 15.13M | 11.99M | 9.38M | 8.05M | 7.80M | 6.50M | 4.75M | 4.55M | 4.29M | 3.56M | 2.73M | 2.27M | 2.06M |
Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022
NORCROSS, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 24th Annual Global Investment Conference being held...
Galectin: Ability To Potentially Target Unmet Medical Need
Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without esophageal varices are expected in Q1 of 2024. If the primary endpoint of the phase 3 NAVIGATE study is met, ability to...
Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress
NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the H.C. Wainwright Global Investment Conference being held from May...
Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference
NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Conference being held virtually January 10-13,...
UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
NORCROSS, Ga., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it will present six scientific abstracts at The Liver Meeting™ 2021, hosted by the American Association...
UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 5th Annual NASH Investor Conference being held...
Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company's management will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The virtual...
Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
NORCROSS, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company's management will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The virtual...
Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis
NORCROSS, Ga., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has recently expanded its management team with multiple key leadership appointments, including Dakshina Reddy,...
GALT Stock Increased 25%: Why It Happened
The stock price of Galectin Therapeutics Inc. (NASDAQ: GALT) increased 25% yesterday. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports